0A0D.LSE Alcon Inc.
- Market cap
- -
- P/E
- 78.7x
- P/B
- -
- ROE
- -
- Dividend yield
- 0.30%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0A0D.LSE undervalued?
Graham numberThe Graham number of Alcon Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Alcon Inc. fundamental analysis
No fundamental analysis for Alcon Inc. yet.
Alcon Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Alcon Inc.
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company's cataract products include Unity CS, Len…
Full company profileAlcon Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Alcon Inc. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.72B | 6.62B | 7.03B | 7.51B | 6.83B | 8.29B | 8.72B | 9.46B | 9.91B | 10.9B | 10.8B |
| Gross Profit | 3.17B | 3.12B | 3.51B | 3.66B | 3.06B | 4.70B | 4.81B | 5.25B | 5.52B | 6.02B | 6.27B |
| Operating Income | 57.0M | 51.6M | 119M | 95.0M | -482M | 580M | 672M | 1.04B | 1.41B | 1.43B | 914M |
| EBITDA | 1.34B | 1.32B | 1.73B | 1.53B | 1.09B | 2.02B | 2.04B | 2.25B | 2.58B | 2.83B | 2.04B |
| Net Income | -173M | 249M | -223M | -656M | -531M | 376M | 335M | 974M | 1.02B | 1.03B | - |
| EPS | -0.35 | 0.51 | -0.46 | -1.34 | -1.09 | 0.76 | 0.68 | 1.96 | 2.05 | 2.07 | - |
| Balance Sheet | |||||||||||
| Total Assets | 28.2B | 26.7B | 26.6B | 27.7B | 27.6B | 28.0B | 29.2B | 29.6B | 30.3B | 31.5B | 31.2B |
| Total Liabilities | 4.81B | 4.25B | 4.35B | 8.35B | 8.78B | 8.74B | 9.49B | 8.99B | 8.79B | 9.51B | 9.53B |
| Shareholders' Equity | 23.4B | 22.4B | 22.3B | 19.3B | 18.8B | 19.3B | 19.7B | 20.6B | 21.6B | 22.0B | 21.7B |
| Cash & Short-term Investments | 165M | 168M | 254M | 855M | 1.57B | 1.58B | 980M | 1.10B | 1.84B | 1.61B | 1.46B |
| Total Debt | - | 84.0M | 89.0M | 3.82B | 4.50B | 4.49B | 5.08B | 5.15B | 5.14B | 5.24B | 5.31B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.27B | 1.19B | 1.12B | 920M | 823M | 1.23B | 1.13B | 1.39B | 2.08B | 2.38B | 1.83B |
| Capital Expenditure | 452M | 404M | 515M | 553M | 479M | 639M | 588M | 660M | 473M | 569M | 463M |
| Free Cash Flow | 816M | 782M | 605M | 367M | 344M | 588M | 537M | 728M | 1.60B | 1.81B | 1.36B |
| Ratios | |||||||||||
| ROE | -0.7% | 1.1% | -1.0% | -3.4% | -2.8% | 2.0% | 1.7% | 4.7% | 4.7% | 4.7% | - |
| ROA | -0.6% | 0.9% | -0.8% | -2.4% | -1.9% | 1.3% | 1.1% | 3.3% | 3.4% | 3.3% | - |
| Net Profit Margin | -2.6% | 3.8% | -3.2% | -8.7% | -7.8% | 4.5% | 3.8% | 10.3% | 10.3% | 9.4% | - |
| Debt to Equity | - | 0.00x | 0.00x | 0.20x | 0.24x | 0.23x | 0.26x | 0.25x | 0.24x | 0.24x | 0.25x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Alcon Inc. dividends
- Dividend yield
- 0.30%
- Forward dividend
- -
- Payout ratio
- 16.9%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | 174M | 0.35 | 16.9% |
| 2024 | USD 130M | 0.26 | 12.8% |
| 2023 | USD 116M | 0.23 | 11.9% |
| 2022 | USD 92.5M | 0.19 | 27.6% |
| 2021 | USD 49.3M | 0.10 | 13.1% |
| 2020 | USD 54.0M | 0.11 | - |
| 2019 | USD 54.0M | 0.11 | - |
| 2018 | USD 54.0M | 0.11 | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Alcon Inc.
- Insiders 0.20%
- Institutions 62.35%
- Public & others 37.46%
- Free float 482M
Alcon Inc. company profile
- Company name
- Alcon Inc.
- Ticker
- 0A0D.LSE
- ISIN
- CH0432492467
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 25,000
- Fiscal year end
- December
- Address
- Chemin de Blandonnet 8, Geneva, Switzerland, 1214
- Phone
- 41 589 112 110
- Website
- alcon.com
About Alcon Inc.
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company's cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. In addition it also develops and commercializes therapies for chronic eye diseases, focusing on encapsulated cell therapy platforms for ocular conditions. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Alcon Inc. management
10- Mr. David J. EndicottCEO & Director · born 1965
- Mr. Timothy C. StonesiferSenior VP & CFO · born 1967
- Mr. Ian BellSenior VP & COO · born 1971
- Margaret BuckleyChief Accounting Officer
- Dr. Franck Leveiller Ph.D.SVP of Global Research & Development and Chief Scientific Officer
- Mr. Muru MurugappanSenior VP and Chief Information & Transformation Officer
- Mr. Daniel CravensVice President of Investor Relations
- Mr. Royce R. Bedward J.D.Senior VP, General Counsel & Corporate Secretary · born 1966
- Ms. Kimberly MartinSenior VP and Chief HR & Corporate Communications · born 1975
- Mr. Leon Sergio Duplan FraustroSenior VP & President of Americas · born 1968